miRNAs in acute myeloid leukemia

Qiong Liao, Bingping Wang, Xia Li _ and Guosheng Jiang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:3666-3682. https://doi.org/10.18632/oncotarget.12343

Metrics: PDF 3114 views  |   HTML 6207 views  |   ?  


Qiong Liao1,2,*, Bingping Wang3,*, Xia Li1,4 and Guosheng Jiang1

1 Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

2 School of Medicine and Life Sciences, Jinan University, Jinan, Shandong, P.R. China

3 Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong, P.R. China

4 Shandong University School of Medicine, Jinan, Shandong, P.R. China

* These authors have contributed equally to this work

Correspondence to:

Xia Li, email:

Guosheng Jiang, email:

Keywords: miRNAs regulatory signaling pathways, acute myeloid leukemia, pathogenesis, prognosis, miRNA-directed therapy

Received: March 29, 2016 Accepted: September 24, 2016 Published: September 29, 2016


MicroRNAs (miRNAs) are small, non-coding RNAs found throughout the eukaryotes that control the expression of a number of genes involved in commitment and differentiation of hematopoietic stem cells and tumorigenesis. Widespread dysregulation of miRNAs have been found in hematological malignancies, including human acute myeloid leukemia (AML). A comprehensive understanding of the role of miRNAs within the complex regulatory networks that are disrupted in malignant AML cells is a prerequisite for the development of therapeutic strategies employing miRNA modulators. Herein, we review the roles of emerging miRNAs and the miRNAs regulatory networks in AML pathogenesis, prognosis, and miRNA-directed therapies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12343